Susquehanna International Group’s Nurix Therapeutics NRIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.04M | Sell |
90,920
-14,751
| -14% | -$168K | ﹤0.01% | 3197 |
|
|
2025
Q1 | $1.26M | Buy |
105,671
+55,985
| +113% | +$665K | ﹤0.01% | 2977 |
|
|
2024
Q4 | $936K | Buy |
49,686
+29,214
| +143% | +$550K | ﹤0.01% | 3102 |
|
|
2024
Q3 | $460K | Sell |
20,472
-36,719
| -64% | -$825K | ﹤0.01% | 3767 |
|
|
2024
Q2 | $1.19M | Buy |
57,191
+6,662
| +13% | +$139K | ﹤0.01% | 2334 |
|
|
2024
Q1 | $743K | Sell |
50,529
-22,011
| -30% | -$324K | ﹤0.01% | 3011 |
|
|
2023
Q4 | $749K | Buy |
72,540
+14,818
| +26% | +$153K | ﹤0.01% | 3275 |
|
|
2023
Q3 | $454K | Sell |
57,722
-33,159
| -36% | -$261K | ﹤0.01% | 3552 |
|
|
2023
Q2 | $908K | Buy |
90,881
+23,322
| +35% | +$233K | ﹤0.01% | 2853 |
|
|
2023
Q1 | $600K | Buy |
67,559
+42,793
| +173% | +$380K | ﹤0.01% | 3566 |
|
|
2022
Q4 | $272K | Sell |
24,766
-24,387
| -50% | -$268K | ﹤0.01% | 4031 |
|
|
2022
Q3 | $640K | Buy |
49,153
+33,378
| +212% | +$435K | ﹤0.01% | 3180 |
|
|
2022
Q2 | $200K | Sell |
15,775
-20,388
| -56% | -$258K | ﹤0.01% | 4565 |
|
|
2022
Q1 | $507K | Sell |
36,163
-5,751
| -14% | -$80.6K | ﹤0.01% | 3693 |
|
|
2021
Q4 | $1.21M | Buy |
41,914
+10,103
| +32% | +$292K | ﹤0.01% | 2598 |
|
|
2021
Q3 | $953K | Buy |
31,811
+4,596
| +17% | +$138K | ﹤0.01% | 2822 |
|
|
2021
Q2 | $722K | Sell |
27,215
-29,703
| -52% | -$788K | ﹤0.01% | 3431 |
|
|
2021
Q1 | $1.77M | Buy |
+56,918
| New | +$1.77M | ﹤0.01% | 2269 |
|